Hepatitis, Cancer Claims Among Those Subject To FDA "Courtesy" Letters
This article was originally published in The Tan Sheet
Executive Summary
Claims to prevent or treat hepatitis and cancer are among statements targeted by FDA in recent "courtesy" letters sent to dietary supplement manufacturers. Washington, D.C.-based Chinese Herb Center received a letter citing claims for Liverin including "It is to be used for chronic hepatitis B, C, D, E and F." Claims for another product, Cervilin, for "cervical syndrome such as cervical bone proliferation and degeneration," also were named in the May 5 letter (see box, p. 9).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC